further demonstrated that CD8+ T cells around the tumor and not those in the TMEs play the most essential role in checkpoint blockade therapies.[86] Therefore, the ability of T cells around the tumor to enter the tumor area may be a key in determining the effect of anti‐tumor immunotherapies. Here, CD8A is linked to neoplasm.